Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Mary Jo Laffler

Executive Editor, US Commercial/R&D News

About Mary Jo

Washington DC, {6D506EDE-F0E4-4964-93FF-D8A3DA23BDA0}

+19 year(s) experience

Mary Jo oversees commercial and R&D news for Informa’s pharmaceutical publications, working with a talented group of reporters and editors covering business and clinical topics. While she has a wide-ranging knowledge of the commercial and regulatory challenges facing the industry, her specialty is analyzing drug development news and R&D strategy.

Mary Jo previously spent more than 15 years reporting on the pharmaceutical industry, including as executive editor and managing editor for Pink Sheet, executive editor for Pharmaceutical Approvals Monthly, and one of the first managing editors for Pink Sheet DAILY (the latter two publications are now part of Pink Sheet content). These roles involved following the drug development process from clinical trials to FDA review to approval and launch, as well as keeping track of broad industry trends and the commercial landscape. This broad experience helps to inform our current coverage. Mary Jo supported development of the FDA Performance Tracker and enjoys working with data to understand the trends affecting the industry.

Specialties

Policy & Regulation
Biopharma Pipeline Strategy
Commercial Strategy

Mary Jo Writes For

Scrip, Pink Sheet

Webinar: What’s the Reality of Real World Evidence?

By Mary Jo Laffler 19 Feb 2019

The data and analysis for this webinar were drawn from Pink Sheet and Scrip, both part of the Informa Pharma Intelligence suite of intelligence solutions.

Full video
Citeline, Scrip, Biomedtracker, Datamonitor Healthcare

ASCO Essentials Webinar 2018 Recording

By Mary Jo Laffler 29 May 2018

Just in time for your 2018 ASCO Annual Meeting planning, join analysts from Datamonitor Healthcare, Biomedtracker, Citeline, Scrip, and Pink Sheet for their expert opinions on what you need to know to get the most from the meeting. Let our experts present their top picks from the thousands of abstracts being presented at ASCO.

Topic Clinical trials

Full video
Scrip

Keytruda Approval Opens New Routes For Immuno-Oncology

By Mary Jo Laffler 30 May 2017

Merck's PD-1 inhibitor holds the first cancer indication based on biomarkers rather than tumor location. The most significant market will be colorectal cancer.

Topic Drug approval

View article
Scrip

What To Look Out For At ACC

By Mary Jo Laffler 14 Mar 2017

Amgen has already reported the positive topline result of its FOURIER cardiovascular outcomes trial for its PCSK9 inhibitor Repatha, but analysts from Datamonitor Healthcare and Biomedtracker lay out the reasons to check out the full results and other highlights at the upcoming American College of Cardiology meeting

View article
Scrip

Oncology Scorecard – Who’s Succeeding At Cancer Drug Development

By Mary Jo Laffler 14 Dec 2016

Using Pharmapremia data, we analyze performance metrics for a select group of leading cancer companies to see where the sticking points are and who is winning at industry’s most important race.

Topic Cancer Strategy Company analysis

View article